Breaking News

Astellas to Acquire Iveric Bio in $5.9B Deal

Advances Astellas' focus on Blindness & Regeneration with lead program Avacincaptad Pegol for the potential treatment of geographic atrophy.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Astellas Pharma Inc. and Iveric bio, Inc. have entered into a definitive agreement under which Astellas through Berry Merger Sub, Inc., a wholly-owned subsidiary of Astellas US Holding, Inc., has agreed to acquire Iveric Bio for a total equity value of approximately $5.9 billion.   The acquisition provides a foundation of ophthalmology focused capabilities, including a commercial team, expansive network of experts in the ophthalmology field, established relationships with medical institutions,...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters